{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:36:59Z","timestamp":1791423419254,"version":"4.3.3"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1093\/cid\/ciy540","type":"journal-article","created":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T13:39:28Z","timestamp":1531575568000},"page":"535-544","source":"Crossref","is-referenced-by-count":159,"title":["Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz\/Emtricitabine\/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus\u20131 Infection: Week 48 Results of the DRIVE-AHEAD Trial"],"prefix":"10.1093","volume":"68","author":[{"given":"Chloe","family":"Orkin","sequence":"first","affiliation":[{"name":"Queen Mary University"},{"name":"Royal London Hospital, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen E","family":"Squires","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[{"name":"University of Paris Diderot, H\u00f4pital Saint-Louis, Assitance Publique H\u00f4pitaux de Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E","family":"Sax","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Wai","family":"Wong","sequence":"additional","affiliation":[{"name":"Taipei Veterans General Hospital, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Sussmann","sequence":"additional","affiliation":[{"name":"Asistencia Cientifica de Alta Complejidad SAS, Bogota, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Desmond Tutu HIV Foundation, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Lupinacci","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xu","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Lin","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Kumar","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sklar","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bach-Yen","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J","family":"Hanna","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey","family":"Hwang","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Martin","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DRIVE-AHEAD Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"key\n\t\t\t\t2019020408492949900_CIT0001","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.idc.2014.06.003","article-title":"Beginning antiretroviral therapy for patients with HIV","volume":"28","author":"Johnson","year":"2014","journal-title":"Infect Dis Clin North Am"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0002","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1128\/AAC.02650-15","article-title":"Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations","volume":"60","author":"Feng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0003","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/AAC.02403-13","article-title":"In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor","volume":"58","author":"Lai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0004","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0005","unstructured":"Sanchez RI , FillgroveK, HafeyM, et al In vitro evaluation of doravirine potential for pharmacokinetic drug interactions. Drug Metab Rev2016; 48(suppl 1):73."},{"issue":"(2)","key":"key\n\t\t\t\t2019020408492949900_CIT0006","doi-asserted-by":"crossref","first-page":"e01364\u201316","DOI":"10.1128\/AAC.01364-16","article-title":"Results of a doravirine-atorvastatin drug-drug interaction study","volume":"61","author":"Khalilieh","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0007","unstructured":"Anderson MS , KaufmanD, CastronuovoP, et al Effect of doravirine (MK-1439) on the pharmacokinetics of an oral contraceptive (Ethinyl Estradiol and Levonorgestrel). Reviews in Antiviral Therapy & Infectious Diseases2015; 4:63\u20134."},{"key":"key\n\t\t\t\t2019020408492949900_CIT0008","unstructured":"Khalilieh S , YeeKL, SanchezRI, et al Co-administration of doravirine with an aluminum\/magnesium containing antacid or pantoprazole, a proton pump inhibitor, does not have a clinically meaningful effect on doravirine pharmacokinetics. Presented at 9th IAS Conference on HIV Science, 23\u201326 July 2017, Paris. Available at: http:\/\/programme.ias2017.org\/PAGMaterial\/eposters\/3996.pdf. Accessed 18 July 2018."},{"key":"key\n\t\t\t\t2019020408492949900_CIT0009","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40261-017-0513-4","article-title":"The effect of single and multiple doses of rifampin on the pharmacokinetics of doravirine in healthy subjects","volume":"37","author":"Yee","year":"2017","journal-title":"Clin Drug Investig"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40261-017-0512-5","article-title":"The effect of food on doravirine bioavailability: results from two pharmacokinetic studies in healthy subjects","volume":"37","author":"Behm","year":"2017","journal-title":"Clin Drug Investig"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0011","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3851\/IMP3142","article-title":"Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects","volume":"22","author":"Behm","year":"2017","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0012","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/jcph.857","article-title":"Moderate hepatic impairment does not affect doravirine pharmacokinetics","volume":"57","author":"Khalilieh","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0013","doi-asserted-by":"crossref","first-page":"19532","DOI":"10.7448\/IAS.17.4.19532","article-title":"Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF\/FTC in ART-naive HIV-positive patients","volume":"17","author":"Gatell","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0014","first-page":"36","article-title":"Efficacy and safety of doravirine 100mg QD vs efavirenz 600mg QD with TDF\/FTC in ART-naive HIV-infected patients: week 24 results","volume":"18","author":"Gatell","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0015","unstructured":"Gatell JM , RaffiF; PlettenbergA, et al Doravirine 100mg QD vs Efavirenz +TDF\/FTC in ART-Naive HIV+ patients: week 48 results. Topics in Antiviral Medicine2016; 24:E\u20131(183)."},{"issue":"(5)","key":"key\n\t\t\t\t2019020408492949900_CIT0016","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0017","volume-title":"Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, version 2.0","author":"Division of AIDS, National Institutues of Health, US Department of Health and Human Services"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0018","volume-title":"Human immunodeficiency virus-1 infection: developing anti-retroviral drugs for treatment, guidance for industry","author":"US Food and Drug Administration"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0019","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0020","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hiv.12004","article-title":"Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials","volume":"14","author":"Stephan","year":"2013","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0021","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0022","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/QAD.0000000000000169","article-title":"Week 48 results from a randomized clinical trial of rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate vs. efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults","volume":"28","author":"Cohen","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0023","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0024","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0025","article-title":"Gilead Sciences, LLC","volume-title":"Prescribing information for ATRIPLA (efavirenz\/emtricitabine\/tenofovir disoproxil fumarate) tablets, for oral use (Revised 01\/2018)"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0026","unstructured":"Marcelin A-G , SantoroMM, CharpentierC, et al Epidemiological study of doravirine associated resistance mutations in HIV-1-infected treatment-naive patients from two large databases in France and Italy. Reviews in Antiviral Therapy & Infectious Diseases2017; 4:10\u201311."},{"key":"key\n\t\t\t\t2019020408492949900_CIT0027","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials","volume":"58","author":"Nachega","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019020408492949900_CIT0028","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMsr077003","article-title":"Statistics in medicine\u2013reporting of subgroup analyses in clinical trials","volume":"357","author":"Wang","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/4\/535\/27699114\/ciy540.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T12:30:57Z","timestamp":1661603457000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/68\/4\/535\/5088828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,8,31]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy540","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2,15]]},"published":{"date-parts":[[2018,8,31]]}}}